梅特福林使用,血压和高血压风险的基因代理治疗效果:基于药物标的孟德尔随机化研究
Junhong Jiang1, Di Hu2, Qi Zhang3
1Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Journal of cardiovascular translational research
|November 27, 2023
概括
使用基因代理的梅特福林可显著降低血压和高血压风险. 特定的药物标,线粒体复合物I和线粒体糖醇3,是其抗高血压作用的关键.
科学领域:
- 药物基因组学 药物基因组学
- 心血管疾病研究研究
- 代谢性疾病研究研究
背景情况:
- 甲胺是一种广泛处方的抗糖尿病药物.
- 它对血压和高血压的影响尚未完全理解.
- 了解药物点可以揭示作用机制.
研究的目的:
- 评估基因代理的甲福明标和血压 (BP) /高血压之间的关联.
- 为了确定对其潜在的抗高血压作用负责的具体甲福明点.
主要方法:
- 进行了基于药物标的门德尔随机化 (MR) 分析.
- 针对五种甲胺的目标 (AMPK,GDF15,MG3,MCI,GCG) 使用了32个仪器变量.
- 针对高血压,缩血压 (SBP) 和腹缩血压 (DBP) 的数据集进行了MR分析.
主要成果:
- 线粒体复合物I (MCI) 和线粒体糖醇3 (MG3) 特定的甲素标显著降低SBP,DBP和高血压风险.
- 基因代理的甲福明使用相当于6.75 mmol/mol HbA1c降低,降低了SBP (β = -1.05,P < 0.001) 和DBP (β = -0.51,P = 0.096).
- 使用甲胺暗示降低高血压风险,而MG3和MCI依赖的效果至关重要.
结论:
- 甲福明的抗高血压功能与其对MCI和MG3标的影响有显著联系.
- 这项研究提供了基因证据,支持甲胺在血压调节中的作用.
- 针对特定目标的MR分析是了解药物机制的宝贵工具.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
582
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
582
01:23Antihypertensive Drugs: Vasodilators
537
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
537
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
748
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
748